HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RAND Report Recommends Case-Control Ephedra Study Look At AE Risk

This article was originally published in The Tan Sheet

Executive Summary

A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states

You may also be interested in...



NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act

RAND Report Author’s Comments Show Bias, Ephedra Education Council Says

Recent comments by Paul Shekelle, MD/PhD and RAND Corp. colleagues represent "a dramatic departure from the objective, peer-reviewed findings of the RAND report" on ephedra, according to Ephedra Education Council General Counsel Wes Siegner

AERs Can Prove Causality – FDA Comments On GAO Ephedra Report

Statements that adverse event reports are not sufficient on their own to establish causality, "while technically true, are not an adequate reflection of current scientific standards for adverse event assessment," FDA states

Related Content

Topics

UsernamePublicRestriction

Register

RS129507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel